Stocks · News reference
Eli Lilly Makes Foundayo Available To Eligible UK Adults Privately, Seeks NICE Assessment For NHS Use At £100-£120 Pricing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 7:42 AM
- Checked
- Aug 24, 2026, 1:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
U.K. Core Retail Sales (MoM) For July -0.9% Vs. -0.5% Est.; 0.9% (Revised) Prior
Read original at benzingaU.K. Core Retail Sales (YoY) For July 2.3% Vs. 3.3% Est.; 5.0% (Revised) Prior
Read original at benzingaObesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
Read original at benzingaEli Lilly Stock Pulls Back After Hitting Record Highs Last Week
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.
Read original at benzingaEli Lilly shares are trading lower. The company reported a real‑world study showing Zepbound cut healthcare costs in adults over 55 with obesity, driven by fewer hospitalizations and ER visits.
Read original at benzinga